AEZS Aeterna Zentaris Inc.

2.90
0  -3%
Previous Close 3.00
Open 3.05
Price To book 9.23
Market Cap 33.84M
Shares 11,670,000
Volume 184,124
Short Ratio 3.18
Av. Daily Volume 295,680

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 4, 2017 - trial failed. Noted March 15 2017, however, that it intends to meet with the FDA at the end of 1Q 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Noted January 30, 2017 completion of Phase 3 trial with data due April 2017.
Zoptrex
Endometrial cancer

Latest News

  1. AETERNA ZENTARIS INC. Financials
  2. Aeterna Zentaris reports 4Q loss
  3. Aeterna Zentaris reports 4Q loss
  4. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
  5. Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™
  6. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
  7. Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society
  8. Tenet Healthcare (THC) to Divest Operations to Amedisys
  9. Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium
  10. Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™
  11. Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
  12. Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference
  13. Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals
  14. Expectations Run High At AEterna Zentaris Inc. (USA) (AEZS) As Two New Drugs Enter Final Testing Phases
  15. Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
  16. Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris
  17. Dryships, Agile Therapeutics in Thursday’s 52-Week Low Club
  18. AEterna Zentaris Inc. (USA) (AEZS) Is Down, But Probably Not Out
  19. 01.04.2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
  20. Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™